<code id='605A7AE5EF'></code><style id='605A7AE5EF'></style>
      • <acronym id='605A7AE5EF'></acronym>
      <center id='605A7AE5EF'><center id='605A7AE5EF'><tfoot id='605A7AE5EF'></tfoot></center><abbr id='605A7AE5EF'><dir id='605A7AE5EF'><tfoot id='605A7AE5EF'></tfoot><noframes id='605A7AE5EF'>
      • <optgroup id='605A7AE5EF'><strike id='605A7AE5EF'><sup id='605A7AE5EF'></sup></strike><code id='605A7AE5EF'></code></optgroup>
        5. <b id='605A7AE5EF'><label id='605A7AE5EF'><select id='605A7AE5EF'><dt id='605A7AE5EF'><span id='605A7AE5EF'></span></dt></select></label></b><u id='605A7AE5EF'></u>
          <i id='605A7AE5EF'><strike id='605A7AE5EF'><tt id='605A7AE5EF'><pre id='605A7AE5EF'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-10-02 19:00:42 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：716
                                  
                                    
          
                                   
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe
          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 
          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?
          advertisement
          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Illumina board agrees to spin off Grail, as divestment plans proceed
                                
                            
          Next article：  
                                      
                                          Medicare details structure of new drug price negotiation program
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles